PLEKHM2-ALK: a novel fusion in small-cell lung cancer and durable response to ALK inhibitors

In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement identifies a subgroup of patients who are sensitive to ALK tyrosine kinase inhibitors (TKIs) [1 –3]. Over the past years, a growing number of ALK rearrangement alterations has been identified in non-small cell lung cancer (NSCLC) predicting response to ALK TKIs treatment [4]. However, ALK fusion is extremely rare in small-cell lung cancer (SCLC). To the best of our knowledge, only two cases of SCLC harboring ALK fusion mutation has been reported previously, both of whom carrying EML4-ALK fusion [5,6].

Source: Lung Cancer - November 5, 2019 Category: Cancer & Oncology Authors: Tao Li, Fan Zhang, Zhaozhen Wu, Longgang Cui, Xiaochen Zhao, Jinliang Wang, Yi Hu Source Type: research